Healthcare industry reported 90 deals worth $25.7 billion in May 2021

Deal value decreased by 16.9 per cent in May 2021, compared to April 2021

In May 2021, the healthcare industry reported 90 deals worth $25.7 billion as compared to the last 12-month average (May 2020 to April 2021) of101 deals worth $22.4 billion.

Soaring Eagle Acquisition Corp, a special purpose acquisition company to acquire Ginkgo Bioworks, a biotech company for $15 billion; Nenelite Limited, an affiliate of Clayton, Dubilier & Rice, LLC to acquire UDG Healthcare plc, a provider of outsourced commercial solutions to healthcare companies for $3.9 billion; and Murano Bidco Limited, a company managed by Carlyle Europe Partners V to acquire Vectura Group plc, a formulation, device design and development company for $1.3 billion were the three major deals that contributed 78 per cent of the total deal value in May 2021.

Deal Date Acquirer (s) Target Deal Value ($ m)
11-May-21 Soaring Eagle Acquisition Corp (US) Ginkgo BioWorks Inc (US) 15,000.0
12-May-21 Nenelite Ltd (Ireland) UDG Healthcare Plc (Ireland) 3,925.4
26-May-21 Murano Bidco Ltd (United Kingdom) Vectura Group Plc (United Kingdom) 1,356.5
6-May-21 Lifesci Acquisition II Corp (US) Science 37 Inc (US) 1,050.0
11-May-21 T. Rowe Price Associates, Inc. (US); Silver Lake Management LLC (US); Fidelity Management & Research Company LLC (US); Coatue Management LLC (US) Caris Life Sciences Inc (US) 830.0

VC investments decreased by 18.3 per cent in May 2021, compared to April 2021

The healthcare industry reported 147 venture capital (VC) deals worth $4.3billion in May 2021, compared to the last 12-month average (May 2020 to April 2021) of 155 deals worth $4.7 billion.

NiKang Therapeutics Inc, a clinical-stage biotech company, raising $200 million in series C financing to advance its lead drug candidates into the clinic, expand the pipeline and fund internal drug discovery program; Hangzhou DAC Biotech Co Ltd, raising $155.4 million in series C financing for R&D of ADC innovative drugs, clinical and optimization of its shareholding structure; and Eikon Therapeutics Inc, a drug discovery and development company, raising $148 million in series A round of financing to develop High-Throughput, Super-Resolution Microscopy for drug discovery were the major VC deals reported in May 2021.

Deal Date Acquirer (s) Target Deal Value ($ m)
26-May-21 BlackRock Inc; Wellington Management Company LLP; Ally Bridge Group; RA Capital Management LP; Invus Group LLC; EcoR1 Capital LLC; Matrix Partners China; Pavilion Capital Partners LLC; RTW Investments LP; HBM Healthcare Investments Ltd; Lilly Asia Ventures; Perceptive Advisors LLC; Cormorant Asset Management LLC; C-Bridge Capital Partners LLC; Casdin Capital LLC; Samsara BioCapital LLC; Janus Henderson Investors; Surveyor Capital Ltd; Logos Global Management LLC; Octagon Capital Advisors LP; PFM Health Sciences LP NiKang Therapeutics Inc (US) 200.0
10-May-21 CITIC Securities Co Ltd; Undisclosed; Citic Private Equity Funds Management Co Ltd; K.Wah International Holdings Ltd; TigerYeah Capital Consulting Co., Ltd; Gaoling (Tianjin) Venture Capital Co., Ltd.; CDG Capital Co. Ltd. Hangzhou DAC Biotech Co Ltd (China) 155.4
5-May-21 The Column Group LLC; Innovation Endeavors; Foresite Capital Management LLC; Lux Capital Eikon Therapeutics Inc (US) 148.0
11-May-21 Viking Global Investors LP; Wellington Management Company LLP; Deerfield Management Company LP; Venrock Healthcare Capital Partners LP; Fidelity Management & Research Company; Driehaus Capital Management LLC; Boxer Capital LLC; Bain Capital Life Sciences; Janus Henderson Investors; Logos Global Management LLC; Avoro Capital Advisors LLC; Fairmount Funds Management LLC Nuvalent Inc (US) 135.0
18-May-21 Amgen Ventures LLC; Ally Bridge Group; Morningside Ventures; Polaris Partners LLC; EDBI Pte Ltd; Mirae Asset Venture Investment Co. Ltd.; Frazier Healthcare Partners; Octagon Capital Group LLC; Novo Holdings AS; Heritas Capital Management Pte Ltd; BB Pureos Bioventures LP; Droia Ventures; Affinity Asset Advisors; Altrium Capital Management Hummingbird Bioscience Pte Ltd (Singapore) 125.0

Source: GlobalData

GlobalDatahealthcare industrypharma dealspharma M&AVC investments
Comments (0)
Add Comment